NCT00784290View on ClinicalTrials.gov

Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

October 31, 2010

Study Completion Date

March 31, 2012

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Orantinib (TSU-68)

200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops

Trial Locations (1)

260-8670

Chiba University Hospital, Inohana Chuo-ku Chiba

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT00784290 - Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter